Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in GIST (POETIG)
NCT03171389Phase 2Unknown
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib in gastrointestinal stromal tumor (GIST) (3 cohorts). Primary endpoint: Clinical Benefit Rate at 16 weeks. Status: unknown.
02
Drugs
ponatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03171389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171389.